Sinomab Bioscience

Executive Summary

Sinomab Bioscience is a private Chinese biotechnology company specializing in monoclonal antibody therapeutics for immunology and oncology. Founded in 2014 and headquartered in Shanghai, the company leverages advanced antibody engineering to develop novel biologic candidates targeting autoimmune diseases and cancers. With a pipeline primarily in Phase 1, Sinomab focuses on addressing significant unmet needs in inflammation and oncology indications. The company's early-stage programs have shown promising preclinical activity, and its proprietary platforms enable the generation of differentiated antibodies with enhanced efficacy and safety profiles. As a private entity, Sinomab is exploring strategic partnerships and funding to advance its assets through clinical development. While still early, the company's expertise in antibody engineering positions it to contribute to the growing biologics market in China and globally.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 Data Readout for Lead Oncology Asset40% success
• Q4 2026IND Filing for New Autoimmune Candidate60% success
• Q2 2027Strategic Partnership or Licensing Deal30% success